Antisense oligonucleotides as inhibitors of genes that regulate AP-1: pharmacology and clinical development.
Dean
N M
NM
ISIS Pharmaceuticals, Inc., Carlsbad, CA 92008, USA.
McKay
R A
RA
Holmlund
J
J
D017322:Clinical Trials, Phase II as Topic; D005786:Gene Expression Regulation / Q000187:drug effects*; D015316:Genetic Therapy; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D005810:Multigene Family / Q000187:drug effects*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology; D009369:Neoplasms / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000235:genetics / Q000502:physiology; D012045:Regulatory Sequences, Nucleic Acid; D015398:Signal Transduction / Q000187:drug effects*; D013329:Structure-Activity Relationship; D018808:Transcription Factor AP-1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D015533:Transcriptional Activation / Q000187:drug effects*
D007527:Isoenzymes; D009363:Neoplasm Proteins; D016376:Oligonucleotides, Antisense; D047428:Protein Kinase Inhibitors; D018808:Transcription Factor AP-1; D011494:Protein Kinases